Fennec Pharmaceuticals opened higher at $10.73, compared with its previous close of $10.64. In the last trading session, the stock traded between $10.26 and $11.64. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Fennec Pharmaceuticals is now worth
$ 116.90
Giving a profit of
$ 16.90 (16.90%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.29 (+2.73%)
Day High
$11.64
Day Low
$10.26
Day Open
$10.73
Prev Close
$10.64
Volume
2,62,872
1W Return
6.01%
1M Return
1.82%
3M Return
-14.53%
6M Return
53.94%
1Y Return
38.01%
Fundamentals
Market Cap ($ Mn)
383
PE Ratio
-
PB Ratio
10.12
PEG Ratio
-
ROE
-413.98%
ROCE
-19.67%
EPS (TTM)
$0.06
Investment Returns
1 Week
6.01%
1 Month
1.82%
3 Months
-14.53%
6 Months
53.94%
9 Months
39.77%
Financials
Quarterly
All values in $ Mn
8.8
Mar 25
9.7
Jun 25
12.5
Sep 25
13.8
Dec 25
15.1
Mar 26
17.9
Jun 26
Updates
12Nov
Fennec Pharmaceuticals Q3FY26 Results: Net sales jump 56% to $19.4 million
Net product sales rose 56% YoY to $19.4 million in Q3FY26. Non-GAAP adjusted EBITDA reached $5.8 million, or 30% of sales. Completed infusions increased 58% sequentially; enrollments up 23%. Secured formulary win at a large Midwestern academic center. Generated record $6.7 million cash from operations with no debt.
Today
15Jun
Fennec Pharmaceuticals grants inducement options to new employee
Fennec Pharmaceuticals Inc. granted 10,000 incentive stock options to a new non-executive employee at $9.00 per share under Nasdaq Rule 5635(c)(4). The options vest over three years, with one-third vesting after one year and the remainder monthly over 24 months. The grants were approved by the Compensation Committee on June 10, 2026.
5mo ago
11Jun
Fennec Pharmaceuticals elects directors at annual meeting
Fennec Pharmaceuticals Inc. elected all director nominees at its AGM held on June 10, 2025. Shareholders approved the appointment of Haskell & White LLP as auditors and ratified executive compensation. Amendments to the 2020 Equity Incentive Plan were also approved by a majority vote.
